{"description":"Toxicities were measured at weekly visit while on therapy using the NCI CTCAE v3.0.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":31,"description":"Erlotinib 150 mg by mouth daily for 3 weeks followed by cystectomy within 24 hours of the last dose.","id":"EG000","otherNumAffected":19,"otherNumAtRisk":31,"seriousNumAffected":5,"seriousNumAtRisk":31,"title":"Pre-surgical Erlotinib Treatment"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"NCI CTCAE V3.0","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":31}],"term":"Rash"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"NCI CTCAE V3.0","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":31}],"term":"Diarrhea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"NCI CTCAE V3.0","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":31}],"term":"Lymphopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"NCI CTCAE V3.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31}],"term":"Decreased Neutrophils/Grabulocytes"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"NCI CTCAE V3.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31}],"term":"Rash"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"NCI CTCAE V3.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Decreased Neutrophils/Grabulocytes"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Endocrine disorders","sourceVocabulary":"NCI CTCAE V3.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Adrenal insufficiency"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"NCI CTCAE V3.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"NCI CTCAE V3.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Infection-wound"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"NCI CTCAE V3.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31}],"term":"Decreased Leukocytes (Total WBD)"}],"timeFrame":"Evaluated for 2 months once drug therapy started."}